DM005 is a bispecific antibody-drug conjugate (ADC) designed to treat solid tumors by targeting both MET and EGFR receptors. The bispecific antibody was assembled using common light chain antibodies produced by RenLite, a fully human antibody mouse originates from Biocytogen. Its monoclonal antibody structure facilitates easy purification and drug conjugation. The structure of bispecific DM005 is a monoclonal antibody with common-light chain, based on the Biocytogen RenLite® Platform, which is stable with high purity. The Linker-Payload of DM005 is named as BLD1102 (topoisomerase inhibitor, TOPi), as described in the following figure.
Briefly, BLD1102 is a new ADC platform developed by Biocytogen independently. BCPT02 is a novel topoisomerase 1 inhibitor with broad-spectrum and potent tumor killing ability. The uniquely designed cleavable linker has excellent hydrophilicity, the hydrophilic properties of ADC is comparable with monoclonal antibody, which greatly improves the physicochemical properties of the ADC. BLD1102-ADC exhibits high stability in plasma and high tumor killing efficacy, making it an excellent next-generation ADC technology platform.
1.DM005 BsAbs showed stronger binding avidity than their parental antibodies, suggesting that DM005 BsAbs improves binding capacity by targeting two antigens with two arms.
Figure1. Binding affinity of DM005
2.DM005 has superior endocytosis activity over parental antibodies in antigen double positive NCI-H1975 cancer cells.
Figure 2. Tumor cell endocytosis
3.DM005 showed outstanding tumor inhibition in CDX model.
Figure 3. DM005 induced dose-dependent tumor inhibition in NSCLC CDX (Balb/c nude mice + NCI-H1975) model.
4.DM005 showed outstanding tumor inhibition in PDX model.
Figure 4. DM005 showed robust anti-tumor effect in PDX (B-NDG mice + BP0508) model.
5.DM005 demonstrated CMC-suitable physiochemical properties.
Related Materials Download
ACCR 2023: Biocytogen-Poster YH013, A Fully-Human EGFR x MET Bispecific ADC Exhibits Outstanding Specificity and Anti-Tumor Efficacy FIN.pdf （YH013 is the former name of DM005）
